I-Mab

Equities

IMAB

US44975P1030

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
1.72 USD +8.86% Intraday chart for I-Mab +7.50% -9.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
I-Mab Appoints Phillip Dennis as Chief Medical Officer CI
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022. CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022. CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023. CI
Verastem Names John Hayslip as Chief Medical Officer MT
I-Mab Announces Chief Medical Officer Changes CI
I-Mab Completes Business Divestiture in China MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab. CI
I-Mab Announces Executive Resignation CI
Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating MT
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials RE
I-Mab Divests China Operations, Shifts Focus to US Market MT
ADRs Close Higher, Renalytix PLC Climbs 96.9% DJ
Biotech firm I-Mab to divest China operations, shift focus to US RE
Biotech firm I-Mab to divest China operations RE
I-Mab Announces Board Changes , Effective February 10, 2024 CI
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million. CI
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab CI
I-Mab Announces Chief Financial Officer Changes CI
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading MT
ADRs Slump; FLJ Group Declines 21% DJ
Chart I-Mab
More charts
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.72 USD
Average target price
7.25 USD
Spread / Average Target
+321.51%
Consensus
  1. Stock Market
  2. Equities
  3. IMAB Stock
  4. News I-Mab
  5. I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers